These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31882645)

  • 1. Evaluation of Selected Outcomes of Combination Antiretroviral Therapy: Yemen Cohort Retrospective Descriptive Studies.
    Nabih MF; Puteh SEW; Nur AM
    Sci Rep; 2019 Dec; 9(1):19923. PubMed ID: 31882645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HIV-Brazil cohort study: design, methods and participant characteristics.
    Grangeiro A; Escuder MM; Cassenote AJ; Souza RA; Kalichman AO; Veloso VG; Ikeda ML; Barcellos NT; Brites C; Tupinanbás U; Lucena NO; da Silva CL; Lacerda HR; Grinsztejn B; Castilho EA
    PLoS One; 2014; 9(5):e95673. PubMed ID: 24789106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in Nigeria, 2004-2012.
    Agolory SG; Auld AF; Odafe S; Shiraishi RW; Dokubo EK; Swaminathan M; Dalhatu I; Onotu D; Abiri O; Debem H; Bashorun A; Ellerbrock TV
    PLoS One; 2017; 12(9):e0183823. PubMed ID: 28863160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis.
    Wilkinson KA; Seldon R; Meintjes G; Rangaka MX; Hanekom WA; Maartens G; Wilkinson RJ
    Am J Respir Crit Care Med; 2009 Oct; 180(7):674-83. PubMed ID: 19628776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.
    Nylén H; Habtewold A; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Diczfalusy U; Aklillu E
    Medicine (Baltimore); 2016 Aug; 95(34):e4631. PubMed ID: 27559961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.
    Bednasz C; Luque AE; Zingman BS; Fischl MA; Gripshover BM; Venuto CS; Gu J; Feng Z; DiFrancesco R; Morse GD; Ma Q
    Curr Vasc Pharmacol; 2016; 14(3):280-7. PubMed ID: 26733388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term response to combination antiretroviral therapy in HIV-infected children in the Netherlands registered from 1996 to 2012.
    Cohen S; Smit C; van Rossum AM; Fraaij PL; Wolfs TF; Geelen SP; Schölvinck EH; Warris A; Scherpbier HJ; Pajkrt D;
    AIDS; 2013 Oct; 27(16):2567-75. PubMed ID: 23842124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
    Sculier D; Gayet-Ageron A; Battegay M; Cavassini M; Fehr J; Hirzel C; Schmid P; Bernasconi E; Calmy A;
    BMC Infect Dis; 2017 Jul; 17(1):476. PubMed ID: 28683720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral therapy improves survival among TB-HIV co-infected patients who have CD4+ T-cell count above 350cells/mm
    Mutembo S; Mutanga JN; Musokotwane K; Alisheke L; Whalen CC
    BMC Infect Dis; 2016 Oct; 16(1):572. PubMed ID: 27751168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of individual drug and combination antiretroviral therapy on trophoblast proliferation.
    Nzuza S; Hadebe SI; Katz AA; Matjila M
    Eur J Obstet Gynecol Reprod Biol; 2024 Jul; 298():66-73. PubMed ID: 38733775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz.
    Harrington BJ; DiPrete BL; Jumbe AN; Ngongondo M; Limarzi L; Wallie SD; Chagomerana MB; Hosseinipour MC;
    Trop Med Int Health; 2019 Oct; 24(10):1221-1228. PubMed ID: 31381233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term evolution of CD4+ cell count in patients under combined antiretroviral therapy.
    Pantazis N; Papastamopoulos V; Paparizos V; Metallidis S; Adamis G; Antoniadou A; Psichogiou M; Chini M; Sambatakou H; Sipsas NV; Gogos C; Chrysos G; Panagopoulos P; Katsarou O; Gikas A; Touloumi G;
    AIDS; 2019 Aug; 33(10):1645-1655. PubMed ID: 31305332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European mitochondrial haplogroups are associated with CD4+ T cell recovery in HIV-infected patients on combination antiretroviral therapy.
    Guzmán-Fulgencio M; Berenguer J; Micheloud D; Fernández-Rodríguez A; García-Álvarez M; Jiménez-Sousa MA; Bellón JM; Campos Y; Cosín J; Aldámiz-Echevarría T; Catalán P; López JC; Resino S
    J Antimicrob Chemother; 2013 Oct; 68(10):2349-57. PubMed ID: 23749950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
    Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
    J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
    Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1405-1415. PubMed ID: 30003275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
    Chéret A; Nembot G; Mélard A; Lascoux C; Slama L; Miailhes P; Yeni P; Abel S; Avettand-Fenoel V; Venet A; Chaix ML; Molina JM; Katlama C; Goujard C; Tamalet C; Raffi F; Lafeuillade A; Reynes J; Ravaux I; Hoën B; Delfraissy JF; Meyer L; Rouzioux C;
    Lancet Infect Dis; 2015 Apr; 15(4):387-96. PubMed ID: 25701561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disparities in Initiation of Combination Antiretroviral Treatment and in Virologic Suppression Among Patients in the HIV Outpatient Study, 2000-2013.
    Novak RM; Hart RL; Chmiel JS; Brooks JT; Buchacz K;
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):23-32. PubMed ID: 25886926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of antiretroviral therapy initiation and treatment outcomes for people living with HIV in Vietnam.
    Tran DA; Shakeshaft A; Ngo AD; Mallitt KA; Wilson D; Doran C; Zhang L
    HIV Clin Trials; 2013; 14(1):21-33. PubMed ID: 23372112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological recovery in tuberculosis/HIV co-infected patients on antiretroviral therapy: implication for tuberculosis preventive therapy.
    Karo B; Krause G; Castell S; Kollan C; Hamouda O; Haas W;
    BMC Infect Dis; 2017 Jul; 17(1):517. PubMed ID: 28743248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up.
    Lin KY; Cheng CY; Li CW; Yang CJ; Tsai MS; Liu CE; Lee YT; Tang HJ; Wang NC; Lin TY; Lee YC; Lin SP; Huang YS; Zhang JY; Ko WC; Cheng SH; Hung CC;
    PLoS One; 2017; 12(6):e0179870. PubMed ID: 28665938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.